ACTIVINS are multifunction cytokines belonging to the TGF-β superfamily and were originally identified by their ability to stimulate follicle-stimulating hormone secretion from the anterior pituitary [1] . In addition to their activities on the pituitary-gonadal axis, activins induce differentiation of erythroid cells and megakaryocytes, modify differentiation of neuronal and neuroendocrine cells, and act as inducers of mesoderm during development [1] [2] [3] . Furthermore, activins modulate cell proliferation and programmed cell death in a variety of tissues [2, 3] .
Activins are secreted as homo-or heterodimmer of related β-subunits. Four β-subunit genes have been identified in humans: β-A, β-B, β-C and β-E. Activin A is a homodimer of the β-A subunit, whereas activin B is a homodimer of β-B [1] . The biological activities of activins are mediated by heterometric receptor complexes consisting of two different types of receptors, type I and type II. Initially, activins bind to the type II receptor, ActRIIA (for activin A) or ActRIIB (for activin B), then the type I receptor, activin-like kinase 4 (ALK4), is recruited and phosphorylated [4] . Phosphorylated ALK4 phosphorylates Smad proteins (Smad2 and Smad3) and then activin signals are transduced into the nucleus [5] .
Various extracellular binding proteins modify the actions of activins. The most important factor modulating the action of activins is an activin-binding protein, follistatin [6] . Follistatin binds to activins with high-affinity and blocks their actions. Follistatin is expressed on the surface of the target cells of activin by binding to the extracellular matrix [7, 8] . Activin trapped by follistatin is internalized by endocytosis and subsequently cleaved by proteolysis. Follistatin is considered to be a local regulator of the activin action. Importantly, activins upregulate the expression of follistatin, which leads to the attenuation of the activin signals. Collectively, the activin-follistatin system is a complex regulatory system that controls diverse cellular functions. In this review, we present the role of the activin-follistatin system in organogenesis, regeneration and tissue fibrosis of the liver, pancreas, kidney and the lung. We also postulate the therapeutic potential of follistatin to promote tissue regeneration and to treat tissue fibrosis.
Liver
In the liver, activin A is mainly expressed in hepatocytes under normal condition. In cultured hepatocytes, addition of activin A attenuates DNA synthesis induced by epidermal growth factor (EGF) or hepatocyte growth factor (HGF) [9] . Activin A also induces cell death of hepatocytes in vitro. In vivo, infusion of activin A evokes dose-dependent loss of liver mass due to hepatocyte apoptosis [10, 11] . In normal liver, mRNA expression of the β-A submit is modest and after partial hepatectomy, mRNA for β-A becomes undetectable within a few hours. Subsequently, mRNA for β-A starts to increase and becomes abundant within 120 hours. Hence, the production of activin A is considerable in the late phase of liver regeneration after partial hepatectomy. The role of activin A is assessed by blocking the action of activin A by an administration of follistatin. Follistatin accelerates liver regeneration and delays the termination of hepatocyte proliferation [12] [13] [14] [15] [16] . Endogenous activin A thus tonically inhibits the regeneration process of the remnant liver. Interestingly, administration of follistatin into intact liver also initiates DNA replication, and the liver mass is increased [17] . Similar results are obtained by introduction of the dominant-negative form of the ActRII gene into hepatocytes [18] . Hence, activins may tonically inhibit growth of hepatocytes even in normal conditions. In agreement with these observations, adenovirus-mediated overexpression of follistatin initiates hepatocyte proliferation in intact liver and enlarges the liver [19] . Taken together, activin A not only exerts tonic inhibition on hepatocyte proliferation in regenerating liver but also blocks growth potential of hepatocytes in intact liver. Activin A is an autocrine inhibitor of hepatocytes and functions to maintain constant liver mass, and follistatin may be useful to promote liver regeneration and increase the liver mass. It is of note that excessive stimulation of hepatocyte growth is not beneficial [20] . Follistatin should be used appropriately to promote liver regeneration.
Recent studies have shown a significant role of activin A in the pathogenesis of liver fibrosis. In carbon tetrachloride (CCl 4 ) treated rat liver, activin A is expressed in hepatocytes and more intensively in hepatic stellate cells (HSC), which secrete excessive extracellular matrix and play a pivotal role in the pathogenesis of liver fibrosis [21] [22] [23] . In these rats, strong immunoreactivity of activin A is observed in HSC transformed into an activated form of myofibroblasts [21] . Immunoreactivities of activin A and α-smooth muscle actin (α-SMA), a marker of activated HSC, are colocalized [24] . In addition, isolated HSC produces activin A and those cells secrete activin A more abundantly when they are activated. Importantly, activin A stimulates the production of collagen and other matrix proteins in HSC [25] . Hence, activin A is an autocrine factor of HSC which stimulates the production of matrix proteins. Activin A is also involved in the action of transforming growth factor-β (TGF-β), a potent stimulator of the production of matrix proteins. Thus, TGF-β stimulates the production of activin A in HSC. The TGF-β-mediated production of activin A is significant since follistatin not only blocks the action of activin A, it also markedly inhibits TGF-β-induced collagen production [25] (Fig. 1) . It is thus expected that follistatin is effective in preventing liver fibrosis. Consistent with this notion, administration of recombinant follistatin to CCl 4 -treated rats attenuates hepatic fibrosis [24] .
These lines of evidence suggest that the activinfollistatin system is involved in both liver regeneration and hepatic fibrosis. Follistatin has a potential to promote liver regeneration and to treat hepatic fibrosis.
Pancreas
In the pancreas, activin A regulates formation and differentiation of endocrine cells. It is expressed in epithelial cells in the pancreatic rudiment and in endocrine precursor cells expressing both insulin and glucagon [26] . It is also known that activins induce the formation and migration of pancreatic islets [27] [28] [29] . Activin A converts pancreatic progenitor cells to endocrine cells [30] by inducing the expression of neurogenin-3 [31] . When combined with betacellulin, a member of the EGF-family, activin A promotes differentiation of pancreatic β cells [32, 33] . Collectively, activin A is an important regulator of differentiation of pancreatic β cells.
Pancreatic stellate cells (PSC) are thought to play an important role in the pathogenesis of pancreatic fibrogenesis. Activated PSC express α-SMA, vigorously proliferate, and produce excessive collagen [34] . In a trinitrobenzene sulfonic acid (TNBS)-treated rat pancreatic fibrosis model and in human tissues obtained from patients with alcoholic pancreatitis, PSC are closely associated with areas of fibrosis and express mRNA for the type I procollagen [35] . PSC express the type I and type II receptors of activin and are activated by activin A. In addition, they produce activin A, which acts as an autocrine factor to augment production of extracellular matrix proteins [36] . Additionally, TGF-β and activin A enhance the production of each other in PSC, and the positive feedback loop is thought to be involved in pancreatic fibrogenesis (Fig. 1) . Thus, TGF-β stimulates the production of activin A, and activin A also stimulates the production of TGF-β. Indeed, both factors augment the production of matrix proteins in PSC [36] . Follistatin blocks the function of activated PSC by shutting off this complex autocrine loops and thereby inhibits production of matrix proteins (Fig. 1) .
Collectively, the activin-follistatin system is involved in development, regenerative processes and fibrogenesis in the pancreas. Follistatin has a therapeutic potential to treat pancreatic fibrosis.
Kidney
The activin-follistatin system is also involved in development of the kidney. Development of metanephric kidney begins at the time of ureteric bud outgrown from the Wolffian duct. Signals from surrounding metanephric mesenchyme are essential for the sprouting of the ureteric bud and for the branching morphogenesis which follows. Among various signals from mesenchyme to the ureteric bud or, conversely, those from the ureteric bud to mesenchyme, activin A plays an important role not only in growth of the ureteric bud but also in differentiation of metanephric mesenchyme. When the ureteric bud emerges from the Wolffian duct, it is thought that glial cell-derived neurotrophic factor (GDNF) is one of the most important factors to promote epithelial budding. In the absence of mesonephros, the Wolffian ducts do not form ectopic bud even in the presence of GDNF. However, perturbation of the activin action allows GDNF to induce ectopic budding. This suggests that the activin signals are normally active in development of the Wolfian duct, and that inactivation of the activin signal is necessary for epithelial budding [37] . In an in vitro tubulogenesis model using epithelial MDCK cells, activin A produced in these cells tonically inhibits branching tubulogenesis. Blockade of the activin signal by follistatin or adenoviral overexpression of the dominantnegative type II activin receptor induces branching morphogenesis [38] . In metanephric organ culture systems, activin A reduces the size of cultured metanephroi, reduces ureteric bud branching, and enlarges the tips of the ureteric bud. In contrast, follistatin increases ureteric bud branching and promotes proliferation of the ureteric bud [39] . In cultured metanephric mesenchymal cells, activin A promotes cell proliferation and induces the expressions of epithelial differentiation markers, such as WT1, Wnt4 and E-cadherin. These results suggest that, during kidney development, activin A produced by the ureteric bud is not only an important regulator of ureteric bud induction and branching morphogenesis but also a differentiation factor for metanephric mesenchyme to epithelial phenotype.
In adult kidney, activin A acts as a negative regulator of regeneration after acute tissue injury. While clamping both renal arteries for 45 min, tubular epithelial cells are exposed to ischemia-reperfusion injury. In this condition, epithelial cells in the outer medulla express activin A, which is not detected in normal kidney, and early phase apoptosis is induced 12 hr after injury. In a normal condition, follistatin is abundantly expressed, which is markedly decreased in acute injury phase. Blockade of the activin signal by exogenous follistatin promotes epithelial cell proliferation, inhibits apoptosis and accelerates tubular regeneration [40] . Follistatin is thus effective in promoting regeneration after renal ischemia.
In fibrotic kidney, TGF-β acts as a profibrotic cytokine by increasing the production of matrix proteins In collagen-producing cells such as myofibrolasts and hepatic and pancreatic stellate cells, activin A activates these cells and induces production of collagen and other matrix proteins (A). TGF-β also activates these cells, and in addition, augments production of activin A. TGF-β and activin A synergistically stimulate the production of collagen and other matrix proteins (B). Follistatin, which blocks the action of activin A, also inhibits the action of TGF-β by blocking the autocrine loop involving activin A (C).
and by reducing matrix turnover and removal. It has also been shown that activin A acts similarly to TGF-β in this process. In an anti-Thy-1 glomerulonephritis model, the expression of activin A is temporally related to injury, matrix accumulation and resolution. In this model, mesangial cells are responsible for extracellular matrix accumulation. Activin A induces TGF-β, PAI-1 and collagen tissue growth factor (CTGF) expression in cultured mesangial cells and promotes collagen production [41] . In tubular fibrosis induced by unilateral ureteral obstruction, activin A is upregulated in tubular cells in the cortex and in the outer medulla [42] . Activin A is also responsible for fibroblast activation and collagen production. It should be mentioned that the action of TGF-β is, at least in part, mediated by an autocrine factor activin A. Follistatin therefore inhibits TGF-β-induced fibrosis in this model [41] (Fig. 1) . The activin-follistatin system is involved in development, regeneration and fibrotic processes of the kidney. In this regard, follistatin has a therapeutic potential to treat acute renal failure and prevent renal fibrosis.
Lung
Like other organs, activin A is involved in a variety of physiology and pathophysiology in the lung.
In a murine asthma model, the activin-follistatin system plays an important role. Expression of activin A, which is secreted mainly from lung mast cells, is increased in the airway. Activin A promotes proliferation of human airway smooth muscle cells and is thought to be involved in airway remodeling [43] . In a remodeled airway, proliferation of fibroblasts and excessive collagen deposition are observed. It is thought that activated, antigen-specific CD4 (+) T-cells play a central role in this process. Serum levels of activin A are increased in patients with severe asthma compared with those in patients with moderate asthma and healthy control subjects [44] . Activin A is expressed in infiltrating lymphocytes and structural cells in the lung. mRNA for β-A is increased in CD4 (+) T-cells of asthmatic patients but mRNA for TGF-β is not. Activin A promotes proliferation of fibroblasts and production of collagen as does TGF-β. Activin A also upregulates the production of TGF-β in fibroblasts and, in turn, TGF-β induces activin A in an even stronger manner. Therefore, activin A is thought to link CD4 (+) T cells to TGF-β and eventually to airway remodeling. In a murine asthma model, activin A and follistatin are increased after allergic challenge. Intranasal administration of follistatin results in decreased activin A concentration in bronchoalveolar lavege fluid (BALF), and decreases the number of cells producing Th2 cytokines and mucus producing cells [45] .
Pulmonary fibrosis is a progressive disorder, characterized by the loss of alveolar structure through the proliferation of fibroblasts and excessive deposition of extracellular matrix. Activin A is expressed in normal bronchiolar epithelium at a low level. In pulmonary fibrosis, strong expression of activin A is found in metaplastic epithelium, hyperplastic smooth muscle cells, desquamated cells and alveolar macrophages [46] . Lung fibroblasts express the type I and type II activin receptors and activin A promotes fibroblast proliferation and differentiation into an activated form of myofibroblast [47] . Activin A also facilitates fibroblast-mediated collagen gel contraction, which resembles contraction and destruction of alveolar structure observed in usual interstitial pneumonia [48] . We have recently shown that activin A is upregulated in the alveolar macrophages in bleomycin-induced pulmonary fibrosis. Administration of follistatin after bleomycin challenge reduces the number of infiltrating inflammatory cells in BALF and ameliorates the early phase of injury [49] . In addition, exogenous follistatin attenuates collagen accumulation and improves lung fibrosis in late phase. In cultured lung fibroblasts, follistatin significantly inhibits TGF-β-induced fibroblast activation and collagen secretion [49] (Fig. 1) . Collectively, the activin-follistatin system plays a significant role in major disorders of the respiratory system. Activin has a possibility to link the immune system to tissue fibrosis and follistatin has a therapeutic potential to treat asthma and pulmonary fibrosis. In addition to organs described above, the activinfollistatin system is also involved in various disorders in other tissues. For example, activin plays a critical role in colonic inflammation and follistatin has a therapeutic potential to treat inflammatory bowel diseases (50) . In addition, activin A is involved in angiogenesis and follistatin may be useful to inhibit pathological angiogenesis (51, 52) . It should be mentioned that we need to evaluate whether or not follistatin has an adverse effect when administered in vivo. As far as we know from animal experiments (12-14, 42, 49) , follistatin does not present any adverse effect. However, since gonadal dysfunction is observed in transgenic mice overexpressing follistatin (52) , further studies are necessary to assess side-effects of follistatin, if any.
In conclusion, the activin-follistatin system is involved in various disorders in many tissues and follistatin has a therapeutic potential to treat such disorders.
